‘Look before you leap’: Caribou to start Ph1 autoimmune study of CAR-T therapy
Just like other cell therapy companies, Caribou Biosciences is entering the autoimmune disease field.
The Berkeley, CA-based biotech disclosed Thursday afternoon that the FDA cleared it to begin a clinical trial of its off-the-shelf cell therapy in lupus, and Caribou expects to start the Phase 1 study by the end of 2024.
Caribou is joining the herd of companies studying cell therapy for autoimmune conditions, where interest has exploded after an academic research group led by Georg Schett from the Friedrich-Alexander University Erlangen-Nürnberg reported striking results in a small group of patients with lupus and other autoimmune disorders. Other companies that have entered into the autoimmune cell therapy field recently include Nkarta and CRISPR Therapeutics.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
